Here's what to expect this week on Diagnostic Imaging.
In this week’s preview, here are some highlights of what you can expect to see coming soon:
It is no secret that screening mammography has a beneficial impact on reducing deaths related to breast cancer. But, what does that effect really look like – how significant can it be? This week, look for coverage of how participating in routine screening mammography actually impacts mortality rates.
For more screening mammography coverage, click here.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
Later this week, the European Congress of Radiology (ECR) will host its 2021 virtual annual meeting. Diagnostic Imaging will bring you the latest news across all the modalities, as well as the details you need for greater workflow productivity and improved facility management. Watch for coverage to begin mid-week.
To review last year’s coverage, click here.
Recent research revealed that transgender patients have had mixed results – at best – with their radiology encounters. Nearly 75 percent of these patients have reported at least one negative experience with an imaging provider. This week, Diagnostic Imaging will publish coverage of a study published in the Journal of the American College of Radiology about best practices for radiologists to provide the highest level of care possible for transgender patients.
For additional coverage on imaging transgender patients, click here.
MRI-Based Deep Learning Algorithm Shows Comparable Detection of csPCa to Radiologists
May 8th 2024In a study involving over 1,000 visible prostate lesions on biparametric MRI, a deep learning algorithm detected 96 percent of clinically significant prostate cancer (csPCa) in comparison to a 98 percent detection rate for an expert genitourinary radiologist.
FDA Clears AI-Powered Qualitative Perfusion Mapping for Cone-Beam CT
May 6th 2024Reportedly validated in more than 10 clinical trials, the AngioFlow perfusion imaging software enables timely identification of brain regions with cerebral blood flow reduction and those with significant hypoperfusion.